Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 4.9% – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) dropped 4.9% on Friday . The stock traded as low as $17.15 and last traded at $17.15. Approximately 307 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 6,895 shares. The stock had previously closed at $18.03.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on AAPG shares. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. Finally, BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat.com, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Price Performance

The firm’s fifty day moving average is $18.21 and its two-hundred day moving average is $21.23. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million for the quarter. On average, analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at approximately $383,000. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International in the second quarter worth approximately $391,000. Finally, UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.